• Candidate genomic biomarkers were revealed for PARPis from genetic interactions. • Gain-of-function mutation of EGFR induced resistance to PARP inhibitors. • Lung cancer may benefit from combination of PARP inhibitor and EGFR inhibitor. • Gene set of biomarkers for PARPis contributes to the prognosis of cancer patients.